Harnessing Artificial Intelligence
This week, AG Mednet's CEO Abraham Gutman spoke to a roundtable of global experts in the biotechnology community. Abraham's presentation focused on harnessing Artificial Intelligence (AI) in pixel de-identification for medical imaging. The event took place May 22-23, 2023, sponsored by the Center for Biomedical Informatics and Information Technology of the National Cancer Institute, a part of the United States National Institutes of Health, the primary U.S. government agency responsible for biomedical research.
Collaboration Leads to Discoveries
Medical imaging is vital to develop new therapies to treat disease. Collaboration and shared data leads to discoveries, yet medical images often contain protected health information (PHI). For this reason, fast and accurate de-identification is critical in the clinical trials ecosystem. AG Mednet's proven Judi Collaboration Platform incorporates best-in-class de-identification. An expert in the field, Abraham Gutman shared his insights with the clinical trials community.
To view the complete roundtable discussion hosted by the National Cancer Institute, click the video link here.
